Search
CHF5633
go.drugbank.com/drugs/DB18696InvestigationalCHF5633 is a fully synthetic pulmonary surfactant preparation comprising DPPC (dipalmitoylphosphatidylcholine), POPG Na (palmitoyl‐oleoyl‐phosphatidylglycerol sodium), a synthetic SP-C analogue, and a
TN-201
go.drugbank.com/drugs/DB18700InvestigationalTN-201 is a gene therapy comprising a native AAV9 capsid with a genomic cassette containing a cardiomyocyte-specific promoter and the wild-type human MYBPC3 gene.
Synonyms: Native AAV9 capsid with a genomic cassette containing a cardiomyocyte-specific promoter and the wild-type human MYBPC3 geneSHR-A1904
go.drugbank.com/drugs/DB18702InvestigationalSHR-A1904 is under investigation in clinical trial NCT04877717 (A Study of SHR-A1904 in Patients With Advanced Solid Cancer).
HTPEP-001
go.drugbank.com/drugs/DB18730ExperimentalHTPEP-001 is a novel peptide that works to inhibit the activation of transforming growth factor beta (TGF-β). It is being investigated for the treatment of fibrosis.[A263527]
BVX-001
go.drugbank.com/drugs/DB18733ExperimentalBVX001 is a a novel, first-in-class CD33/CD7-directed antibody-drug conjugate.
Ompenaclid
go.drugbank.com/drugs/DB18819InvestigationalRGX-202 is a recombinant AAV8 that contains a vector genome encoding a miniaturized dystrophin protein (microdystrophin).
Avizakimab
go.drugbank.com/drugs/DB18842InvestigationalAvizakimab is under investigation in clinical trial NCT03371251 (Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care).
Elsubrutinib
go.drugbank.com/drugs/DB18850InvestigationalElsubrutinib is under investigation in clinical trial NCT04451772 (A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants
Galegenimab
go.drugbank.com/drugs/DB18860InvestigationalGalegenimab is under investigation in clinical trial NCT03972709 (A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to
Naporafenib
go.drugbank.com/drugs/DB18865InvestigationalNaporafenib is under investigation in clinical trial NCT06346067 (A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With Nras-mutant Melanoma (SEACRAFT-2)).